Hepatocellular carcinoma, currently the sixth most common malignancy and the third leading cause of cancer-related death globally, is facing a paradigm shift in precision management according to a comprehensive review published in Cancer Biology & Medicine. Researchers from the Eastern Hepatobiliary Surgery Hospital at Naval Medical University in Shanghai and the First Affiliated Hospital of Henan University outline a surgery-centered framework designed to address early detection, precision surgery, and recurrence prevention across the entire care continuum.
Why Conventional Screening Falls Short in Early-Stage Detection
Traditional diagnostic tools often miss early-stage cases, leaving most patients diagnosed at intermediate or advanced stages. According to the review published in August 2026 (Volume 23, Issue 8, DOI: 10.20892/j.issn.2095-3941.2026.0045), conventional ultrasound and alpha-fetoprotein screening fail to detect approximately 30 to 40 percent of early-stage tumors. This diagnostic gap fuels high recurrence rates following surgery, where the five-year recurrence rate approaches 70 percent even among patients who undergo successful curative-intent resection. Early recurrences stem from occult micrometastases, while late recurrences arise from underlying chronic liver disease.
Did you know? The rising global burden of metabolic dysfunction-associated steatotic liver disease is actively reshaping the epidemiological landscape of liver cancer, adding new complexity to clinical management strategies.
Multi-Parameter Biomarkers and Liquid Biopsies
To overcome the limitations of alpha-fetoprotein alone, investigators point to multi-parameter models that achieve area under the receiver operating characteristic curve (AUROC) values exceeding 0.85 across various etiologies. The GALAD score incorporates gender, age, alpha-fetoprotein, its Lens culinaris agglutinin-reactive fraction (AFP-L3), and des-gamma-carboxy prothrombin (DCP). Meanwhile, the more cost-effective ASAP score utilizes age, sex, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist-II (PIVKA-II). Additionally, circulating tumor DNA methylation-based liquid biopsies show immense promise for spotting hepatocellular carcinoma at stages amenable to curative intervention.
Advancements in Precision Surgery and Conversion Therapy
Surgical management is evolving alongside diagnostic biomarkers. The China Liver Cancer (CNLC) staging system demonstrates distinct advantages over the Barcelona Clinic Liver Cancer (BCLC) system, particularly for intermediate-stage patients, by offering higher homogeneity and monotonicity in survival prediction. Furthermore, conversion therapy combining immunotherapy with locoregional treatments successfully expands surgical opportunities for patients with initially unresectable hepatocellular carcinoma.
Evidence from high-volume Asian centers shows that aggressive surgical approaches provide meaningful survival advantages in carefully selected patients. The randomized phase 2/3 CARES-009 trial established that perioperative therapy with camrelizumab (a PD-1 inhibitor) and rivoceranib (a VEGFR-2 inhibitor) significantly improves event-free survival compared to surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence.
Pro Tip: Integrating circulating tumor DNA-based minimal residual disease monitoring into postoperative surveillance can facilitate dynamic, personalized adjuvant therapy decisions based on real-time molecular evidence.
Targeting Occult Micrometastases Through Perioperative Treatment
Addressing occult micrometastatic disease remains critical to lowering post-surgical recurrence rates. According to the review authors, the perioperative treatment group in the CARES-009 trial achieved a major pathological response rate of 35.1 percent, compared to just 7.5 percent in the surgery-alone group. This data supports ongoing investigations into perioperative treatment as a strategy to address occult micrometastatic disease.
“We need to think of this as a continuous care pathway,” the authors stated regarding the shift toward unified clinical strategies. They emphasized that early detection, surgical precision, and recurrence prevention function as mutually reinforcing components rather than isolated clinical events.
Frequently Asked Questions
Why do conventional screenings miss early-stage hepatocellular carcinoma?
Conventional ultrasound and alpha-fetoprotein screening miss roughly 30 to 40 percent of early-stage cases, which is why researchers advocate for multi-parameter models like the GALAD and ASAP scores.
What is the benefit of the CNLC staging system?
The China Liver Cancer staging system demonstrates higher homogeneity and monotonicity in survival prediction compared to the Barcelona Clinic Liver Cancer system, particularly for intermediate-stage patients.
What did the CARES-009 trial demonstrate?
The randomized phase 2/3 trial showed that perioperative therapy combining camrelizumab and rivoceranib significantly improved event-free survival and yielded a major pathological response rate of 35.1 percent compared to surgery alone.
Join the Conversation
How are clinical practices in your region adapting to these new multi-parameter biomarker scores and perioperative immunotherapy frameworks? Share your thoughts or clinical experiences in the comments below, and subscribe to our newsletter for the latest updates in oncology research.
Related reading